
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3986489/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG) Tj ETQq1 1	0.784314 6.3	rgBT /Overlo 75
2	541-553. Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers. Cancer Gene Therapy, 2021, 28, 18-26.	2.2	6
3	A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer. Clinical Cancer Research, 2021, 27, 3028-3038.	3.2	4
4	Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma. Nature Communications, 2021, 12, 1454.	5.8	20
5	The association between obesity and weight loss after bariatric surgery on the vaginal microbiota. Microbiome, 2021, 9, 124.	4.9	14
6	Oncologist-led BRCA â€~mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management. Scientific Reports, 2020, 10, 3390.	1.6	34
7	[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1239-1251.	3.3	12
8	Proteomic analysis of malignant and benign endometrium according to obesity and insulin-resistance status using Reverse Phase Protein Array. Translational Research, 2020, 218, 57-72.	2.2	7
9	Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions. Nature Communications, 2019, 10, 3134.	5.8	9
10	<p>Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification</p> . Journal of Pain Research, 2019, Volume 12, 2039-2052.	0.8	58
11	Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome. Annals of Surgical Oncology, 2019, 26, 2943-2951.	0.7	54
12	Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker. Radiology, 2019, 293, 374-383.	3.6	25
13	<p>Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population</p> . Hepatic Medicine: Evidence and Research, 2019, Volume 11, 47-67.	0.9	10
14	A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer. Nature Communications, 2019, 10, 764.	5.8	130
15	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet, The, 2019, 394, 2084-2095.	6.3	142
16	Risk factors for endometrial cancer: An umbrella review of the literature. International Journal of Cancer, 2019, 145, 1719-1730.	2.3	290
17	Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells. Cancer Biology and Therapy, 2019, 20, 21-30.	1.5	14
18	Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer. Neoplasia, 2018, 20, 280-288.	2.3	23

#	Article	IF	CITATIONS
19	Clinical value of bioelectrical properties of cancerous tissue in advanced epithelial ovarian cancer patients. Scientific Reports, 2018, 8, 14695.	1.6	7
20	Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study. British Journal of Cancer, 2018, 119, 815-822.	2.9	35
21	Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study) British Journal of Cancer, 2018, 119, 330-338.	2.9	13
22	Biomarker Assessment of HR Deficiency, Tumor <i>BRCA1/2</i> Mutations, and <i>CCNE1</i> Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy. Molecular Cancer Research, 2018, 16, 1103-1111.	1.5	83
23	Copy number signatures and mutational processes in ovarian carcinoma. Nature Genetics, 2018, 50, 1262-1270.	9.4	320
24	The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. EMBO Reports, 2018, 19, .	2.0	30
25	Anti-tumorigenic and Platinum-Sensitizing Effects of Apolipoprotein A1 and Apolipoprotein A1 Mimetic Peptides in Ovarian Cancer. Frontiers in Pharmacology, 2018, 9, 1524.	1.6	18
26	Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective. Journal of Clinical Oncology, 2017, 35, 587-590.	0.8	38
27	British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 213, 123-139.	0.5	64
28	Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy–Innovative Models Prolong Survival (OCTIPS) Consortium. European Journal of Cancer, 2017, 79, 214-225.	1.3	29
29	Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study. British Journal of Cancer, 2017, 116, 1287-1293.	2.9	22
30	Endocrine therapy in epithelial ovarian cancer. Expert Review of Anticancer Therapy, 2017, 17, 109-117.	1.1	41
31	A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2017, 23, 7621-7632.	3.2	31
32	WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response. Cell Death and Disease, 2017, 8, e2955-e2955.	2.7	37
33	The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer. Molecular Cancer Therapeutics, 2017, 16, 2246-2256.	1.9	24
34	Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer. Clinical Cancer Research, 2017, 23, 2213-2222.	3.2	83
35	Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ: British Medical Journal, 2017, 356, j477.	2.4	539
36	Obesity and gynaecological and obstetric conditions: umbrella review of the literature. BMJ: British Medical Journal, 2017, 359, j4511.	2.4	107

#	Article	IF	CITATIONS
37	Integrative Analysis of Subcellular Quantitative Proteomics Studies Reveals Functional Cytoskeleton Membrane–Lipid Raft Interactions in Cancer. Journal of Proteome Research, 2016, 15, 3451-3462.	1.8	15
38	TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial–mesenchymal transition. Cell Death and Disease, 2016, 7, e2522-e2522.	2.7	40
39	Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer. International Journal of Oncology, 2016, 49, 1651-1665.	1.4	34
40	The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype–specific therapeutic target for ovarian cancer. Science Signaling, 2016, 9, ra97.	1.6	105
41	Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy. Oncotarget, 2016, 7, 7216-7226.	0.8	29
42	A phase Ib study of NUC1031 and carboplatin for patients with recurrent ovarian cancer Journal of Clinical Oncology, 2016, 34, 5565-5565.	0.8	2
43	The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma. Oncotarget, 2015, 6, 31593-31603.	0.8	39
44	Whole–genome characterization of chemoresistant ovarian cancer. Nature, 2015, 521, 489-494.	13.7	1,206
45	Dose-Finding Quantitative ¹⁸ F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies. Journal of Nuclear Medicine, 2015, 56, 1828-1835.	2.8	24
46	The Next Steps in Improving the Outcomes of Advanced Ovarian Cancer. Women's Health, 2015, 11, 355-367.	0.7	8
47	Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. European Journal of Cancer, 2015, 51, 1978-1988.	1.3	44
48	A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway. Oncotarget, 2015, 6, 41736-41749.	0.8	22
49	The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future. British Medical Bulletin, 2014, 112, 57-69.	2.7	19
50	Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures. Modern Pathology, 2014, 27, 433-442.	2.9	13
51	ProGem1: A phase I/II study of a first-in-class nucleotide, Acelarin, in patients with advanced solid tumors Journal of Clinical Oncology, 2014, 32, 2531-2531.	0.8	5
52	Evolving concepts in the management of drug resistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance. Cancer Treatment Reviews, 2013, 39, 153-160.	3.4	53
53	ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors Journal of Clinical Oncology, 2013, 31, 2576-2576.	0.8	7
54	The OPCML Tumor Suppressor Functions as a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer. Cancer Discovery, 2012, 2, 156-171.	7.7	50

#	Article	IF	CITATIONS
55	Evaluation of 2-Deoxy-2-[18F]Fluoro-D-glucose- and 3′-Deoxy-3′-[18F]Fluorothymidine–Positron Emission Tomography as Biomarkers of Therapy Response in Platinum-Resistant Ovarian Cancer. Molecular Imaging and Biology, 2012, 14, 753-761.	1.3	23
56	Epithelial Ovarian Cancer. , 2012, , 760-775.		2
57	Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer, 2011, 11, 719-725.	12.8	1,084
58	Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer. Journal of Clinical Oncology, 2011, 29, 3798-3804.	0.8	203
59	HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer. Cancer Research, 2011, 71, 4412-4422.	0.4	159
60	Targeting the AKT Pathway in Ovarian Cancer. , 2011, , 73-94.		3
61	Targeting locoregional peritoneal dissemination in ovarian cancer. Expert Review of Obstetrics and Gynecology, 2009, 4, 133-147.	0.4	7
62	Endometrioid epithelial ovarian cancer. Cancer, 2008, 112, 2211-2220.	2.0	89
63	The IgLON Family in Epithelial Ovarian Cancer: Expression Profiles and Clinicopathologic Correlates. Clinical Cancer Research, 2005, 11, 5764-5768.	3.2	49
64	Carcinosarcoma of the ovary. Cancer, 2004, 100, 2148-2153.	2.0	133
65	OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nature Genetics, 2003, 34, 337-343.	9.4	169
66	Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression. Cancer Research, 2003, 63, 8648-55.	0.4	29
67	Current clinical trials in ovarian cancer. , 0, , 205-222.		0

68 Epithelial Ovarian Cancer. , 0, , 625-635.

1